Armata Pharmaceuticals Inc. is a leading biotechnology company committed to transforming the treatment of bacterial diseases. With a strong corporate philosophy centered around innovation, dedication, and patient-centric solutions, Armata strives to deliver life-saving therapies for high unmet medical needs. The company values transparency, scientific excellence, and collaboration to address the global healthcare challenges posed by antibiotic-resistant infections. Through its extensive research and development efforts, Armata Pharmaceuticals Inc. aims to revolutionize the field of antimicrobial therapeutics, providing hope for patients and healthcare professionals worldwide.

Armata Pharmaceuticals Inc primarily operates in the United States.

Armata Pharmaceuticals Inc has achieved several significant milestones. The company successfully completed a merger with C3J Therapeutics, Inc. in 2019, expanding its research and development capabilities. In the same year, Armata Pharmaceuticals initiated a Phase 1 clinical study of its lead product candidate, AP-SA01, for the treatment of Staphylococcus aureus infections. In 2020, the company received FDA Fast Track designation for AP-PA02, another candidate for the treatment of Pseudomonas aeruginosa infections. These milestones highlight Armata Pharmaceuticals' advancements in developing innovative therapies to address serious and drug-resistant bacterial infections, solidifying its position as a leader in the field.

Armata Pharmaceuticals Inc is a biotechnology company that specializes in developing phage-based therapeutics to combat antibiotic-resistant infections. Founded in 2018, Armata Pharmaceuticals emerged from the merger of two phage therapy companies, AmpliPhi Biosciences Corporation and C3J Therapeutics Inc. By leveraging its proprietary bacteriophage platform, Armata aims to address the growing global threat of antibiotic resistance. The company's rigorous research and development activities focus on creating novel phage-based products to target multidrug-resistant bacteria. With a commitment to transforming the treatment landscape, Armata Pharmaceuticals Inc is dedicated to providing innovative solutions for patients suffering from serious and life-threatening infections.

The main competitors of Armata Pharmaceuticals Inc in the market are companies such as ContraFect Corporation, AmpliPhi Biosciences Corporation, and AvidBiotics Corporation.

Armata Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Armata Pharmaceuticals Inc. is centered around developing and commercializing bacteriophage-based therapies to treat antibiotic-resistant infections. As a biotechnology company, Armata focuses on leveraging the potential of phage technology to address the growing global health threat posed by multidrug-resistant bacteria. By targeting specific bacteria strains, their therapeutic platforms aim to provide effective and innovative solutions for life-threatening infections. Armata Pharmaceuticals Inc. employs a research-driven approach and strategic partnerships to develop novel therapies and ultimately improve patient outcomes in the fight against antibiotic resistance.

P/E-forholdet til Armata Pharmaceuticals er −2,19.

Armata Pharmaceuticals KUV er 26,74.

AlleAktien kvalitetsscore for Armata Pharmaceuticals er 7/10.

forventede Armata Pharmaceuticals omsetningen er 3,14 mill. USD.

forventede Armata Pharmaceuticals -gevinsten er −38,38 mill. USD.

Armata Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of bacteriophage-based treatments for infections. The company is divided into two business segments: the antibody platform and the phage platform. The antibody platform focuses on the identification and development of monoclonal antibodies for the treatment of severe infectious diseases such as MRSA or Clostridium difficile. This platform utilizes the ability of antibodies to target specific structures on pathogenic bacteria. The goal is to develop safe and effective treatment options for patients whose infections cannot be treated with conventional antibiotics. The phage platform specializes in the research and development of bacteriophages. Bacteriophages are viruses that specialize in infecting and destroying bacteria. Armata's phage platform focuses on the identification and development of phages that target bacteria harmful to human health. The aim of the platform is to develop more effective and broadly applicable treatments for infections that are no longer responsive to conventional antibiotics. Armata is focused on researching treatments for bacterial infectious diseases, which are becoming increasingly common and can have serious consequences for patients' health. By using new and innovative technologies and developing products that counteract resistant bacterial strains, Armata's products are of great interest to the healthcare sector. Armata aims to provide innovative and life-saving drugs that help meet the growing demand for effective treatment options for infections. The company collaborates closely with scientists and other companies to leverage the latest developments in biotechnology and ensure that its products meet the highest quality standards. Armata has already launched several products on the market, including AR-301, a monoclonal antibody for the treatment of Staphylococcus aureus infections, and AP-SA01, a phage-based treatment for Staphylococcus aureus. The company is also working on the development of additional products to expand the range of therapeutic options. Overall, Armata Pharmaceuticals is a promising biotech company specializing in the development of treatments that aim to address the current need for effective treatments for infectious diseases. The company utilizes advanced technologies such as antibodies and phages to develop new and innovative product solutions that contribute to improving the well-being of patients worldwide.

Armata Pharmaceuticals utbetaler et dividende på 0 USD fordelt over utdelinger i året.

Utbyttet kan for øyeblikket ikke beregnes for Armata Pharmaceuticals eller så utdeler ikke selskapet utbytte.

ISIN-en til Armata Pharmaceuticals er US04216R1023.

WKN for Armata Pharmaceuticals er A2PKLC.

Tikkeren til Armata Pharmaceuticals er ARMP.

I løpet av de siste 12 månedene utbetalte Armata Pharmaceuticals et utbytte på . Dette tilsvarer en utbytteavkastning på ca. . For de neste 12 månedene vil Armata Pharmaceuticals sannsynligvis betale et utbytte på 0 USD.

Utdelingsrendementet til Armata Pharmaceuticals er for øyeblikket .

Armata Pharmaceuticals betaler utbytte kvartalsvis. Dette blir utdelt i månedene .

Armata Pharmaceuticals betalte utbytte hvert år de siste 0 årene.

For de kommende 12 månedene forventes det utbytter på 0 USD. Dette tilsvarer en utbytteavkastning på 0 %.

Armata Pharmaceuticals tilordnes sektoren 'Helse'.

For å motta den siste utbyttet fra Armata Pharmaceuticals den på 0 USD, måtte du ha aksjen i porteføljen din før ex-datoen den .

Utbetalingen av det siste utbyttet fant sted den .

I løpet av 2023 ble det utbetalt 0 USD i utbytte fra Armata Pharmaceuticals.

Utdelingene fra Armata Pharmaceuticals blir betalt ut i USD.